A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|HER2+ Breast Cancer
Interventions: BIOLOGICAL: VRP-HER2|BIOLOGICAL: Pembrolizumab
Sponsor: Herbert Lyerly
Collaborators: Merck Sharp & Dohme LLC